ERBB2 and neoplasm: The Prosigna (PAM50) test provides not only a molecular, gene expression profile-based classification of the tumor (luminal A, luminal B, HER2-enriched, basal like), but also provides a risk of recurrence (ROR) score, this may help in estimating the prognosis (89).